GH Research PLC(NASDAQ:GHRS) 
GH Research is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Website: https://www.ghres.com/
Founded: 2018
Sector: Manufacturing
Industry: Medicinal and Botanical Manufacturing
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2025-03-31 | 2025-02-27 | 2023-09-30 | 2023-06-30 |
|---|---|---|---|---|
operating expenses | ||||
research and development | -7,852 | -35,016,000 | -7,088 | -7,176 |
general and administration | -4,880 | -15,296,000 | -2,631 | -2,749 |
income from operations | -12,732 | -50,312,000 | -9,719 | -9,925 |
yoy | ||||
qoq | -99.97% | 517566.43% | -2.08% | |
finance income | 2,759 | 9,873,000 | 2,438 | 2,122 |
finance expense | -178 | -717,000 | -184 | -179 |
movement of expected credit loss | -19 | 66,000 | -17 | 217 |
foreign exchange (loss)/gain | -642 | |||
total other income | 1,920 | 11,351,000 | 4,070 | 2,196 |
income before tax | -10,812 | -38,961,000 | -5,649 | |
tax charge/ | ||||
loss for the period | -10,812 | -5,649 | ||
other comprehensive income/ | ||||
items that may be reclassified to profit or loss | ||||
fair value movement on marketable securities | 60 | -173,000 | -428 | -1,512 |
currency translation adjustment | 532 | -2,054,000 | -1,780 | -57 |
total comprehensive loss for the period | -10,220 | -7,857 | -9,298 | |
attributable to owners: | ||||
loss per share | ||||
basic and diluted loss per share | -0.19 | -0.75 | -0.11 | |
foreign exchange gain/ | 2,129,000 | 36 | ||
loss for the year | -38,961,000 | |||
other comprehensive (expense)/income | ||||
total comprehensive loss for the year | -41,188,000 | |||
assets | ||||
current assets | ||||
cash and cash equivalents | 100,791 | |||
other financial assets | 19,387 | |||
marketable securities | 29,146 | |||
other current assets | 4,901 | |||
total current assets | 154,225 | |||
non-current assets | ||||
property, plant and equipment | 748 | |||
total non-current assets | 34,048 | |||
total assets | 188,273 | |||
liabilities and equity | ||||
current liabilities | ||||
trade payables | 3,741 | |||
lease liability | 255 | |||
other current liabilities | 4,957 | |||
total current liabilities | 8,953 | |||
non-current liabilities | ||||
total non-current liabilities | 369 | |||
total liabilities | 9,322 | |||
equity attributable to owners | ||||
share capital | 1,301 | |||
additional paid-in capital | 291,463 | |||
other reserves | 5,194 | |||
foreign currency translation reserve | -12,561 | |||
accumulated deficit | -106,446 | |||
total equity | 178,951 | |||
total liabilities and equity | 188,273 | |||
foreign exchange gain | 1,833 | |||
other comprehensive expense | ||||
(loss)/profit before tax | -7,729 | |||
(loss)/profit for the period | -7,729 | |||
(loss)/earnings per share | ||||
basic and diluted | -0.15 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-06-18 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | |||||||||||||||||||
current assets | |||||||||||||||||||
cash and cash equivalents | 249,654 | 253,873 | 100,791 | 244,954 | 100,791 | 90,059 | 87,131 | 77,483 | 78,420,000 | 86,439 | 96,895 | 105,082 | 165,955,000 | 256,939 | 265,377 | 270,750 | 276,776,000 | ||
other financial assets | 19,387 | 12,558 | 19,387 | 32,517 | 41,965 | 51,346 | 55,615,000 | 55,494 | 54,728 | 54,057 | |||||||||
marketable securities | 38,853 | 37,662 | 33,300 | 33,835 | 29,146 | 27,461 | 22,219 | 29,029 | 27,525,000 | 19,343 | 13,761 | 3,682 | 85,724,000 | ||||||
other current assets | 6,283 | 2,345 | 4,901 | 3,321 | 4,901 | 4,909 | 1,596 | 2,618 | 2,529,000 | 2,765 | 1,015 | 1,896 | 2,586,000 | 3,100 | 856 | 2,713 | 3,066,000 | 4,816 | 164 |
total current assets | 294,790 | 293,880 | 154,225 | 294,668 | 154,225 | 154,946 | 152,911 | 160,476 | 164,089,000 | 164,041 | 166,399 | 164,717 | 168,541,000 | 260,039 | 266,233 | 273,463 | 279,842,000 | 285,561 | 292,789 |
non-current assets | |||||||||||||||||||
property, plant and equipment | 692 | 739 | 748 | 705 | 748 | 859 | 896 | 975 | 1,069,000 | 1,078 | 1,176 | 1,221 | 97,000 | 84 | 86 | 81 | 82,000 | 73 | 30 |
other non-current assets | 1,162 | 1,658 | 1,090 | ||||||||||||||||
total non-current assets | 7,232 | 19,548 | 34,048 | 25,786 | 34,048 | 44,665 | 54,065 | 57,107 | 62,211,000 | 68,527 | 73,873 | 84,542 | 85,821,000 | 84 | 86 | 81 | 82,000 | 73 | 30 |
total assets | 302,022 | 313,428 | 188,273 | 320,454 | 188,273 | 199,611 | 206,976 | 217,583 | 226,300,000 | 232,568 | 240,272 | 249,259 | 254,362,000 | 260,123 | 266,319 | 273,544 | 279,924,000 | 285,634 | 292,819 |
liabilities and equity | |||||||||||||||||||
current liabilities | |||||||||||||||||||
trade payables | 3,837 | 3,447 | 3,741 | 4,774 | 3,741 | 2,946 | 2,572 | 3,554 | 3,490,000 | 2,707 | 2,912 | 2,928 | 1,868,000 | 1,750 | 1,707 | 1,545 | 883,000 | 1,214 | 1,002 |
lease liability | 365 | 364 | 369 | 336 | 255 | 275 | 263 | 336 | 343,000 | 260 | 267 | 334 | |||||||
other current liabilities | 6,206 | 6,155 | 4,957 | 4,808 | 4,957 | 6,566 | 4,967 | 3,385 | 2,868,000 | 3,167 | 3,378 | 3,376 | 2,678,000 | 1,635 | 1,388 | 2,521 | 1,866,000 | 819 | 3,590 |
total current liabilities | 10,408 | 9,966 | 8,953 | 9,918 | 8,953 | 9,787 | 7,802 | 7,275 | 6,701,000 | 6,134 | 6,557 | 6,638 | 4,546,000 | 3,385 | 3,095 | 4,066 | 2,749,000 | 2,033 | 4,592 |
non-current liabilities | |||||||||||||||||||
total non-current liabilities | 217 | 283 | 369 | 322 | 369 | 458 | 497 | 561 | 631,000 | 661 | 732 | 791 | |||||||
total liabilities | 10,625 | 10,249 | 9,322 | 10,240 | 9,322 | 10,245 | 8,299 | 7,836 | 7,332,000 | 6,795 | 7,289 | 7,429 | 4,546,000 | 3,385 | 3,095 | 4,066 | 2,749,000 | 2,033 | 4,592 |
equity attributable to owners | |||||||||||||||||||
share capital | 1,551 | 1,551 | 1,301 | 1,551 | 1,301 | 1,301 | 1,301 | 1,301 | 1,301,000 | 1,301 | 1,301 | 1,301 | 1,301,000 | 1,301 | 1,301 | 1,301 | 1,301,000 | 1,301 | 1,301 |
additional paid-in capital | 431,061 | 431,061 | 431,061 | 291,463 | 291,463 | 291,463 | 291,463 | 291,463,000 | 291,448 | 291,448 | 291,448 | 291,448,000 | 291,448 | 291,448,000 | |||||
other reserves | 10,708 | 8,407 | 6,671 | 5,194 | 4,866 | 3,713 | 4,293 | 4,651,000 | 2,888 | 2,809 | 3,870 | 2,595,000 | 1,578 | 1,159 | 693 | 366,000 | 131 | 12 | |
foreign currency translation reserve | -11,635 | -11,572 | -12,029 | -12,561 | -10,620 | -12,242 | -11,796 | -10,507,000 | -13,196 | -11,416 | -11,359 | -13,035,000 | -21,682 | -15,218 | -5,903,000 | -3,333 | -488 | ||
accumulated deficit | -140,288 | -126,268 | -117,040 | -106,446 | -97,644 | -85,558 | -75,514 | -67,940,000 | -56,668 | -51,159 | -43,430 | -32,493,000 | -15,907 | -15,466 | -10,037,000 | -5,946 | -4,110 | ||
total equity | 291,397 | 303,179 | 178,951 | 310,214 | 178,951 | 189,366 | 198,677 | 209,747 | 218,968,000 | 225,773 | 232,983 | 241,830 | 249,816,000 | 256,738 | 263,224 | 269,478 | 277,175,000 | 283,601 | 288,227 |
total liabilities and equity | 302,022 | 313,428 | 188,273 | 320,454 | 188,273 | 199,611 | 206,976 | 217,583 | 226,300,000 | 232,568 | 240,272 | 249,259 | 254,362,000 | 260,123 | 266,319 | 273,544 | 279,924,000 | 285,634 | 292,819 |
share premium | 304,426 | 291,448 | 291,512 | ||||||||||||||||
share-based compensation reserve | 4,904 | ||||||||||||||||||
additional paid-in-capital | 291,448 | 291,448 | |||||||||||||||||
cash | 280,745 | 292,625 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities | -17,044 | -10,808 | ||||||||||||||
loss for the period | -14,020 | -10,812 | -12,114 | -10,379 | -7,666 | -5,649 | -7,729 | -10,937 | -441 | -1,836 | ||||||
depreciation | 89 | 76 | 314,763 | 79 | 78 | 80 | 314,763 | 80 | 80 | 77 | 46,966 | 12 | 11 | 11 | 18,990 | 6 |
share-based compensation expense | 2,334 | 1,635 | 1,170,588 | 273 | -138 | 277 | 2,289,351 | 647 | 451 | 551 | 1,669,788 | 419 | 466 | 327 | 365,869 | 119 |
finance income | -2,783 | -2,759 | -9,865,240 | -2,535 | -2,555 | -2,670 | -8,971,951 | -2,438 | -2,122 | -1,489 | ||||||
finance expense | 21 | 178 | 716,462 | 181 | 178 | 179 | 722,466 | 184 | 179 | 171 | 8,991 | 3 | ||||
movement of expected credit loss | -30 | 19 | -65,955 | 2 | 3 | -50 | -999 | 17 | ||||||||
foreign exchange loss | 642 | |||||||||||||||
movement in working capital | -2,902 | 213 | 187,188 | -1,425 | 1,680 | 557 | 1,643,881 | -2,054 | 700 | 2,473 | 2,158,196 | -1,850 | 987 | 1,667 | -555,822 | -4,669 |
finance expense paid | -100 | -172 | -722,300 | -334 | -197 | -169 | -647,534 | -186 | -34 | -246 | ||||||
finance income received | 3,462 | 2,407 | 7,071,232 | 1,721 | 1,860 | 1,187 | 4,280,727 | 892 | 702 | 679 | ||||||
net cash from operating activities | -13,682 | -8,573 | -42,253,161 | -12,307 | -9,936 | -9,596 | -33,310,749 | -10,340 | -8,026 | -6,885 | -26,179,668 | -8,045 | -15,271,475 | -9,757 | ||
capital expenditures | -39 | -4 | -48,976 | -4 | -8 | -12 | -99,924 | -8 | -46 | -22 | -66,951 | -15 | -103,915 | -50 | ||
free cash flows | -13,721 | -8,577 | -42,302,137 | -12,311 | -9,944 | -9,608 | -33,410,673 | -10,348 | -8,072 | -6,907 | -26,246,619 | -8,060 | -15,375,390 | -9,807 | ||
cash flows from investing activities | 9,784 | 11,838 | ||||||||||||||
purchase of property, plant and equipment | -39 | -4 | -48,976 | -4 | -8 | -12 | -99,924 | -8 | -46 | -22 | -66,951 | -15 | -103,915 | -50 | ||
proceeds from sale of other financial assets | 0 | 7,000 | 10,000 | 10,000 | 5,000 | |||||||||||
proceeds from redemptions and disposals of marketable securities | 9,823 | 4,842 | 27,165,172 | 5,288 | 9,740 | 3,800 | ||||||||||
cash flows from financing activities | ||||||||||||||||
payment of lease liability | -66 | -303,755 | -60 | -114 | -71 | -218,837 | -56 | -37 | -70 | |||||||
proceeds from equity public offering | 0 | 150,000 | ||||||||||||||
transaction costs from equity public offering | 0 | -9,142 | ||||||||||||||
net cash flows from financing activities | -66 | 140,858 | 286,160,382 | -2,602 | ||||||||||||
net increase in cash and cash equivalents | -3,964 | 144,123 | ||||||||||||||
cash and cash equivalents at the beginning of the period | 0 | 100,791 | 0 | 0 | 78,420 | |||||||||||
impact of foreign exchange on cash and cash equivalents | -255 | 40 | -174,919 | 11 | -34 | -58 | 105,026 | |||||||||
cash and cash equivalents at the end of the period | -4,219 | 244,954 | 2,928 | 9,648 | 77,483 | |||||||||||
foreign exchange gain | -7,160,488 | -6,185 | ||||||||||||||
loss for the year | ||||||||||||||||
cash flows from/(used) in investing activities | ||||||||||||||||
purchase of other financial assets | -53,946,000 | 0 | 0 | -54,000 | ||||||||||||
proceeds from sale of other financial asset | ||||||||||||||||
proceeds from share issuances | ||||||||||||||||
cash and cash equivalents at the beginning of the year | ||||||||||||||||
cash and cash equivalents at the end of the year | ||||||||||||||||
foreign exchange (gain)/loss | -466 | -1,321 | ||||||||||||||
cash flows used in operating activities | -48,602,093 | -13,694 | -11,599 | -10,614 | -36,943,942 | -11,046 | -8,694 | -7,318 | -26,657,668 | -8,045 | -15,262,484 | -9,754 | ||||
cash flows from/(used in) investing activities | 65,091,196 | 15,284 | 19,732 | 8,788 | ||||||||||||
purchase of marketable securities | ||||||||||||||||
cash flows used in financing activities | ||||||||||||||||
net cash flows used in financing activities | ||||||||||||||||
net increase/(decrease) in cash and cash equivalents | 22,534,280 | 2,917 | ||||||||||||||
foreign exchange loss/ | -36 | 1,637 | ||||||||||||||
net decrease in cash and cash equivalents | -879 | |||||||||||||||
cash flows used in investing activities | -54,045,924 | -8 | -46 | -54,022 | ||||||||||||
cash flows (used in)/from financing activities | ||||||||||||||||
transaction costs from share issuances | ||||||||||||||||
net cash flows (used in)/from financing activities | ||||||||||||||||
net (decrease)/increase in cash and cash equivalents | ||||||||||||||||
net decrease in cash | -8,109 | -60,977 | ||||||||||||||
cash at the beginning of the period | 0 | 165,955 | 0 | 0 | 276,776 | 0 | ||||||||||
impact of foreign exchange on cash | -78 | 104 | 66,456 | -378 | -178,842 | 529 | ||||||||||
cash at the end of the period | -8,187 | 105,082 | -8,438 | -5,373 | 270,750 | -11,880 | ||||||||||
the accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements. | ||||||||||||||||
expected credit loss | 199 | |||||||||||||||
net finance (income)/expense | ||||||||||||||||
proceeds from capital contributions | 308,890,800 | 0 | ||||||||||||||
transaction costs from capital contributions | -22,730,418 | -2,602 | ||||||||||||||
cash at the beginning of the year | ||||||||||||||||
net (decrease)/increase in cash | -8,060 | |||||||||||||||
gh research plc | ||||||||||||||||
notes to the unaudited condensed consolidated interim financial statements | ||||||||||||||||
foreign exchange translation differences | -5,903,623 | |||||||||||||||
interest paid | -3 | |||||||||||||||
net increase/(decrease) in cash | -12,409 | |||||||||||||||
1. |